This article has been cited by
1Reverse Signaling of Tumor Necrosis Factor Superfamily Proteins in Macrophages and Microglia: Superfamily Portrait in the Neuroimmune Interface
Won-Ha Lee,Donggun Seo,Su-Geun Lim,Kyoungho Suk
Frontiers in Immunology.2019;10()
[DOI]
2PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
Xue Han,Matthew D. Vesely,Wendy Yang,Miguel F. Sanmamed,Ti Badri,Jude Alawa,Francesc López-Giráldez,Patricia Gaule,Sang Won Lee,Jian-Ping Zhang,Xinxin Nie,Ala Nassar,Agedi Boto,Dallas B. Flies,Linghua Zheng,Tae Kon Kim,Gilbert W. Moeckel,Jennifer M. McNiff,Lieping Chen
Science Translational Medicine.2019;11(522)eaax1159
[DOI]
3Recent Advances in Lupus B Cell Biology: PI3K, IFN?, and Chromatin
Maria A. Bacalao,Anne B. Satterthwaite
Frontiers in Immunology.2021;11(522)eaax1159
[DOI]
4Belimumab
R. Gläser
Der Hautarzt.2012;63(3)253
[DOI]
5Genetics and novel aspects of therapies in systemic lupus erythematosus
Manfred Relle,Julia Weinmann-Menke,Eva Scorletti,Lorenzo Cavagna,Andreas Schwarting
Autoimmunity Reviews.2015;14(11)1005
[DOI]
6Expert Perspective: An Evidence-Based Approach to Refractory Cutaneous Lupus Erythematosus
Robert Borucki,Victoria P. Werth
Arthritis & Rheumatology.2020;72(11)1777
[DOI]
7Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies
Marilyn E. Allen,Violeta Rus,Gregory L. Szeto
Trends in Molecular Medicine.2021;27(2)152
[DOI]
8Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies
Samvedna Saini,Yatender Kumar
Trends in Molecular Medicine.2021;27(2)233
[DOI]
9Could GILZ Be the Answer to Glucocorticoid Toxicity in Lupus?
Jacqueline K. Flynn,Wendy Dankers,Eric F. Morand
Frontiers in Immunology.2019;10(2)233
[DOI]
10Successful treatment of two cases of refractory cutaneous lupus erythematosus with belimumab
Xavier Bosch-Amate,Daniel Morgado-Carrasco,Andrea Combalia,Priscila Giavedoni,Gerard Espinosa,José M. Mascaró
Indian Journal of Dermatology, Venereology and Leprology.2021;87(2)421
[DOI]
11Candidate drug replacements for quinacrine in cutaneous lupus erythematosus
Daisy Yan,Robert Borucki,Richard D Sontheimer,Victoria P Werth
Lupus Science & Medicine.2020;7(1)e000430
[DOI]
12Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
Dominik Samotij,Adam Reich
BioMed Research International.2019;2019(1)1
[DOI]
13TERAPIA BIOLÓGICA - BELIMUMABE NO LÚPUS ERITEMATOSO SISTÊMICO: REVISÃO SISTEMÁTICA DA LITERATURA
M.M. Santos,I.V.S. Lima
Revista Brasileira de Reumatologia.2017;57(1)S202
[DOI]
14Tratamiento del lupus eritematoso sistémico: mitos, certezas y dudas
Guillermo Ruiz-Irastorza,Alvaro Danza,Munther Khamashta
Medicina Clínica.2013;141(12)533
[DOI]
15Tratamiento del lupus eritematoso sistémico: mitos, certezas y dudas
Doreen E. Szollosi,Clinton B. Mathias,Jeremy P. McAleer
Medicina Clínica.2020;141(12)67
[DOI]
16Use of polyclonal/monoclonal antibody therapies in transplantation
Melissa Y. Yeung,Steven Gabardi,Mohamed H. Sayegh
Expert Opinion on Biological Therapy.2017;17(3)339
[DOI]
17Autophagy: A new concept in autoimmunity regulation and a novel therapeutic option
Srinivasa Reddy Bonam,Fengjuan Wang,Sylviane Muller
Journal of Autoimmunity.2018;94(3)16
[DOI]
18An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice
Jay Patel,Robert Borucki,Victoria P. Werth
Current Rheumatology Reports.2020;22(10)16
[DOI]
19An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice
Scott S. De Rossi,Katharine N. Ciarrocca
Current Rheumatology Reports.2015;22(10)201
[DOI]
20Neutrophils in the Pathogenesis of Rheumatoid Arthritis and Systemic Lupus Erythematosus: Same Foe Different M.O.
Michele Fresneda Alarcon,Zoe McLaren,Helen Louise Wright
Frontiers in Immunology.2021;12(10)201
[DOI]
  Feedback 
  Subscribe